Copyright
©The Author(s) 2023.
World J Hepatol. Feb 27, 2023; 15(2): 123-128
Published online Feb 27, 2023. doi: 10.4254/wjh.v15.i2.123
Published online Feb 27, 2023. doi: 10.4254/wjh.v15.i2.123
Table 1 Metabolic-associated fatty liver disease endorsement by societies, groups, and stakeholders
| Type of endorsement | Endorsed by | Ref. |
| Guidelines | APASL | [25] |
| Guidelines | Egyptian EMRG group | [26] |
| Consensus statement | Middle East and North Africa group | [27] |
| View point (perspectives) | International nurse and allied health groups | [28] |
| Position statement | ALEH | [29] |
| Position statement | The Chinese Society of Hepatology | [30] |
| Position statement | ISTP | [31] |
| Position statement | Arabic Association for the Study of Diabetes and Metabolism | [32] |
| Consensus statement | Malaysian Society of Gastroenterology and Hepatology | [33] |
| Viewpoint (perspectives) | International leaders in regulatory science and drug development | [34] |
| Position statement | International representatives of patient advocacy groups | [35] |
| Letter of endorsement | Global multi-stakeholder from more than 135 countries worldwide | [36] |
| Editorial of endorsement | Spanish Society of Gastroenterology | [37] |
- Citation: Fouad Y. Metabolic-associated fatty liver disease: New nomenclature and approach with hot debate. World J Hepatol 2023; 15(2): 123-128
- URL: https://www.wjgnet.com/1948-5182/full/v15/i2/123.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i2.123
